DGX · Quest Diagnostics Incorporated

Quest Diagnostics issued $500 million of 5.000% senior notes due 2036, a significant debt financing event. The notes are senior unsecured obligations ranking equally with existing and future senior unsecured debt. Interest is payable semi-annually, and the notes mature in 2036. The indenture includes customary covenants limiting liens, sale and leaseback transactions, and consolidation/merger/asset transfers. A change of control triggering event would require the company to offer to repurchase the notes at 101% of principal plus accrued interest. This issuance provides long-term capital for general corporate purposes, likely refinancing or funding growth initiatives. The terms are standard for investment-grade issuers, and the transaction was executed under an existing indenture framework, indicating efficient capital markets access.